The CASP6 Knockout AGS Polyclonal Cells are a CRISPR/Cas9-mediated polyclonal gene disruption model in the AGS human gastric adenocarcinoma cell line. This product comprises a heterogeneous population of cells with targeted genomic modifications at the CASP6 locus, generating a loss-of-function system for the executioner caspase-6. The polyclonal format provides robust gene ablation while avoiding clonal variability, enabling consistent functional studies in a well-characterized epithelial cancer model.
AGS cells are an adherent human gastric adenocarcinoma cell line with epithelial morphology, originally derived from a gastric cancer patient. They serve as a widely used model for studying signal transduction, drug response, and the molecular mechanisms of gastric carcinogenesis. Their gastric mucosal epithelial origin renders them relevant for research on mucosal barrier function, inflammatory signaling, and apoptotic regulation. The introduction of a CASP6 knockout into this background offers a targeted tool to dissect caspase-6-specific roles in gastric epithelial cell biology.
CASP6 is an executioner caspase activated by upstream initiator caspases CASP8, CASP9, and CASP10, as well as granzyme B, upon apoptotic stimulation. Once activated, it cleaves structural proteins including lamin A/C (LMNA), lamin B1 (LMNB1), keratin 18 (KRT18), and ??II-spectrin (SPTAN1), leading to nuclear lamina disassembly and cytoskeletal breakdown. Its activity is inhibited by XIAP, which directly binds caspases, and it interacts with other regulators like BIRC5 (survivin). In the apoptotic cascade, CASP6 functions downstream of CASP8 and CASP9, with BID bridging extrinsic and intrinsic pathways, and converges with CASP3 to execute cell death. Beyond apoptosis, CASP6 contributes to inflammasome signaling and neurodegeneration, where its aberrant activation cleaves tau and APP in Alzheimer’s disease.
In AGS gastric adenocarcinoma cells, CASP6 knockout provides a physiologically relevant system to explore the role of executioner caspases in gastric cancer cell death and survival. Gastric cancers frequently display dysregulated apoptosis pathways, contributing to chemoresistance and tumor progression. Eliminating CASP6 allows assessment of its contribution to drug-induced apoptosis, examination of compensatory mechanisms among other caspases, and evaluation of chemosensitivity. Furthermore, this model enables investigation of non-apoptotic functions of CASP6, such as potential involvement in NF-??B activation or cytokine processing, which are pertinent to gastric mucosal inflammation and H. pylori pathogenesis.
This polyclonal knockout cell product supports diverse applications in apoptosis research, drug discovery, and cancer biology. Standard assays include western blotting for CASP6 protein and RT-qPCR for mRNA validation, Annexin V/PI flow cytometry for apoptosis quantification, fluorogenic caspase activity measurements, and chemosensitivity testing via MTT or clonogenic survival assays. Co-immunoprecipitation enables interactome mapping, while immunofluorescence detects cleaved lamin A/C to visualize nuclear apoptotic events. These tools facilitate mechanistic studies of caspase-6-dependent cell death, caspase inhibitor screening, and testing of gastric cancer therapeutics. For further information, please contact Ascent Research.
